RxDoctor Payments Data

David Jacoboff, MD

Interventional Cardiology · Roswell, GANPI 1215957030

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $61,200 of the $64,199 with a category attached, or 95.3%. Edwards Lifesciences accounts for 95.4% of it on its own, with 31 other manufacturers making up the rest. Reporting peaked in 2022 at $31,082 and has fallen 98.8% since, to $360 in 2025.

$64,199in general payments, 2019–2025

Across 151 payments — averaging $425.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$61K
  • Johnson & Johnson$371
  • Novartis$345
  • Boehringer Ingelheim$316
  • Amgen$300
  • Pfizer$274
  • plus $1K from 26 others

What the payments were for

  • Consulting fees$61,20095%
  • Food & beverage$2,9995%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$64,199 in reported general payments places this provider in the 85th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$184,751
Medicare patients
883
Services billed
3,645

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban423$449,189
JardianceEmpagliflozin170$147,593
BrilintaTicagrelor116$93,710
EntrestoSacubitril/Valsartan77$72,132
XareltoRivaroxaban32$41,820
FarxigaDapagliflozin Propanediol14$20,206
Repatha SureclickEvolocumab14$13,183
Atorvastatin Calcium487$4,385
Metoprolol Succinate349$4,170
Rosuvastatin Calcium247$3,755
Ranolazine ErRanolazine31$2,950
Carvedilol357$2,870
Losartan Potassium212$2,525
Ezetimibe78$1,710
Hydralazine Hcl84$1,510

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$274$449,189423 claims
Boehringer IngelheimJardiance$316$147,593170 claims
AstraZenecaBrilinta, Farxiga$54$113,916130 claims
NovartisEntresto$345$72,13277 claims
Johnson & JohnsonXarelto$371$41,82032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Roswell

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →